Shawn Leland, Fore Biotherapeutics interim CEO
August 23, 2023 10:30 AM EDT
Financing
Startups

Fore scores $75M Se­ries D, tees up new lead­er­ship with ex-El­e­va­tion CEO Shawn Le­land at the helm — for now

Kyle LaHucik

Senior Reporter

Fore Bio­ther­a­peu­tics has reeled in a $75 mil­lion Se­ries D, and its CEO Matthew Ros is walk­ing off the course for “oth­er pro­fes­sion­al pur­suits,” the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roche’s TIG­IT drug tiragolum­ab flunks an­oth­er Phase 3 lung can­cer test

Cir­cle Phar­ma rais­es $54M as part of Se­ries D while macro­cy­cles heat up

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

UK trade group slams No­vo, No­var­tis, Pfiz­er and Ot­su­ka for code breach­es

Ex­perts want to make it eas­i­er to get RSV vac­cines. Did they make it hard­er in­stead?

Pfiz­er adds ex-State Street CEO to the board; Two Merus ex­ecs head for the ex­it

A service from the Financial Times